Step by Step


ABIM MOC Activity ID

5/1/2018 - Medical Grand Rounds: Cardiovascular Effects of Incretin-based Anti-Diabetic Therapies





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Know which incretin-based therapies cause weight loss and reduce cardiovascular mortality.
  • Name three differences between GLP-1 analogs and DPP4 inhibitors.
  • Describe a potential drug-drug interaction between ACE inhibitors and DPP inhibitors.
  • Name potential side effects of GLP-1 analogs.

Suggested Additional Reading:

  1. UKPDS study group Lancet 1998; 352: 854
  2. Nauck M et al. Diabetologia 1986
  3. Drucker and Nauck Lancet 2006
  4. Knudsen LB et al. J Med Chem 2000
  5. Yamamoto et al J Clin Invest 2002
  6. Trahair et al J Clin Endocrinol Metab 2014
  7. Wu et al Diabetic Med 2014

Nancy J. Brown, MD — Hugh Jackson Morgan Professor of Medicine and Pharmacology. Chair of the Department of Medicine, and Physician-in-Chief at Vanderbilt Hospital
Dr. Brown receives grant support from NIH, AHA, Novo Nordisk, Shire Pharmaceuticals. She is a consultant with Novartis Pharmaceuticals, Shire Pharmaceuticals, and Viamet Pharmaceuticals, Alnylam Pharmaceuticals
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.